Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics to Present at Upcoming Investor Conferences
11:00am, Thursday, 04'th Jun 2020
Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat. A live webcast and archive of the William Blair event can be viewed on the "Webcasts & Presentat
Jazz Pharmaceuticals: Pandemic Leaves The Leading Drug In A Catch 22 (NASDAQ:JAZZ)
04:56pm, Monday, 01'st Jun 2020
As the pandemic fears squeeze the new patient enrollments for Xyrem, JAZZ has downgraded the revenue guidance. While the economic downturn stifles the revenue g
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3
Is Axsome Therapeutics a Buy?
04:57pm, Tuesday, 26'th May 2020
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?
Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually
11:00am, Tuesday, 26'th May 2020
Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeti
Better Buy: Biogen vs. Axsome Therapeutics
11:36am, Saturday, 23'rd May 2020
One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.
What's Behind Axsome Therapeutics' Miracle Pipeline?
10:04am, Tuesday, 19'th May 2020
Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses
03:56pm, Monday, 11'th May 2020
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript
06:00pm, Saturday, 09'th May 2020
During today's call, we will be making certain forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, a
Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
12:10pm, Saturday, 09'th May 2020
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
Is Axsome Therapeutics a Screaming Buy?
10:47am, Saturday, 09'th May 2020
The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ: AXSM), notching two wins and one failure in late-stage clinical trials. On March 30, the company reported its drug AXS-05 fail
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
11:00am, Friday, 08'th May 2020
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further.
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda
12:00am, Friday, 08'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 7)
• Acceleron Pharma Inc (...
Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April
07:39pm, Sunday, 03'rd May 2020
Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P; Global Market Intelligence. March was a rough month for
